Vertaling van "pfizer’s annual " (Frans → Nederlands) :

TERMINOLOGIE

virus Mason-Pfizer du singe
Mason-Pfizer apenvirus

IN-CONTEXT TRANSLATIONS

Pfizer Hosts Annual Meeting Of Shareholders Declares 20-Cent Second-Quarter 2011 Dividend
Pfizer Declares A 20-Cent Third-Quarter 2011 Dividend

Pfizer Invites Public To Listen To Webcast Of April 26 Annual Meeting Of Shareholders
Pfizer Hosts Annual Meeting Of Shareholders Declares 22-Cent Second-Quarter 2012 Dividend

NEW YORK, N.Y., November 3 - Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Olivier Brandicourt, President and General Manager, Primary Care, at the 2010 Annual Credit Suisse Healthcare Conference on Wednesday, November 10, 2010 at 8:00 a.m.
NEW YORK , N.Y. , June 29 - Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 3, 2010.

To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “2010 Annual Credit Suisse Healthcare Conference” link in the Investor Presentations section located on the lower right-hand corner of that page.
To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Quarterly Corporate Performance – Second Quarter 2010” link in the Investor Presentations tab on our homepage.

This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.

A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K.
A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K. # # # # #